"3"^^ . "3"^^ . "Umo\u017En\u00ED zkvalitnit pr\u00E1ci na vlastn\u00EDm pracovi\u0161ti. Pops\u00E1ny d\u00EDl\u010D\u00ED n\u00E1lezy ohledn\u011B exprese sledovan\u00FDch antigen\u016F CD 20 a CD 52."@cs . . . "Density of CD20 and CD52 antigens expression on tumor cells in patients with tumors of lymphoid origin in relation to monoclonal antibody treatment"@en . "1"^^ . "http://www.isvav.cz/projectDetail.do?rowId=NR9023"^^ . . . "1"^^ . . . . . "Monoclonal antibodies became a significant and standard part of treatment of various types of cancer. In hematooncology, rituximab (anti-CD20] and alemtuzumab (anti-CD52) are widespread used in treatment of non-Hodgkin's lymphomas and chronic leukemias. The aim of thid project is to determine quantitatively the expression of CD20 and CD52 in MESF units on the tumor cells of lymphomas and leukemias with quantitative multiparametric flow cytometry. CD20 and CD52 expression on tumor cells and normal lymphocytes will be compared. In patients treated with antibody, the response to the treatment, minimal residual disease and antigen density after the treatment will be evaluated. The results will have an impact to the correct indication of monoclonal antibody treatment in particular diagnosis, optimization of dosage and effectiveness of treatment, and indication of retreatment with antibodies in the case or relapsing disease."@en . "0"^^ . " density of antigen" . . . "2008-12-31+01:00"^^ . . . "Denzita exprese antigenu CD20 a CD52 na populaci n\u00E1dorov\u00FDch bun\u011Bk u pacient\u016F s n\u00E1dory typu lymfoproliferac\u00ED ve vztahu k l\u00E9\u010Db\u011B monoklon\u00E1ln\u00EDmi protil\u00E1tkami" . "NR9023" . " CD20" . . " CD52" . . "2011-04-27+02:00"^^ . " non-hodgkin's lymphoma" . "Monoklon\u00E1ln\u00ED protil\u00E1tky se v\u00FDznamn\u011B pod\u00EDlej\u00ED na l\u00E9\u010Db\u011B \u0159ady n\u00E1dor\u016F. V hematoonkologii maj\u00ED nej\u0161ir\u0161\u00ED uplatn\u011Bn\u00ED protil\u00E1tky rituximab (anti-CD20) a alemtuzumab (anti-CD52) v l\u00E9\u010Db\u011B non-hodgkinsk\u00FDch lymfom\u016F a chronick\u00FDch lymfoidn\u00EDch leuk\u00E9mi\u00ED. C\u00EDlem projektu je stanovit kvantitativn\u011B expresi antigen\u016F CD20 a CD52 v jednotk\u00E1ch MESF na n\u00E1dorov\u00FDch bu\u0148k\u00E1ch lymfom\u016F a leuk\u00E9mi\u00ED pomoc\u00ED kvantitativn\u00ED multiparametrick\u00E9 flow cytometrie. Exprese antigen\u016F CD20 a CD52 na n\u00E1dorech bude srovn\u00E1na s expres\u00ED na fyziologick\u00FDch lymfocytech. U pacient\u016F l\u00E9\u010Den\u00FDch protil\u00E1tkou bude sledov\u00E1na odpov\u011B\u010F na l\u00E9\u010Dbu, minim\u00E1ln\u00ED rezidu\u00E1ln\u00ED nemoc a densita exprese antigen\u016F po ukon\u010Den\u00E9 l\u00E9\u010Db\u011B. V\u00FDsledky projektu budou m\u00EDt v\u00FDznam pro spr\u00E1vn\u00E9 stanoven\u00ED indikac\u00ED l\u00E9\u010Dby u dan\u00E9 diagn\u00F3zy, optimalizaci d\u00E1vkovac\u00EDch sch\u00E9mat a \u00FA\u010Dinnosti l\u00E9\u010Dby a indikaci retreatmentu monoklon\u00E1ln\u00EDmi protil\u00E1tkami anti-CD20 a anti-CD52 v p\u0159\u00EDpad\u011B relapsu nemoci." . . "2008-03-05+01:00"^^ . "leukemia; non-hodgkin's lymphoma; CD20; CD52; monoclonal antibodies; density of antigen; rituximab; alemtuzumab"@en . . "2006-01-01+01:00"^^ . . " rituximab" . "leukemia" . " monoclonal antibodies" . "It will enhance the work of their own department. Describes partial findings on the controlled expression of CD 20 and CD 52 antigen."@en . .